Immunohistochemical expressions of Cap43 and Mina53 proteins in neuroblastoma.
BACKGROUND
We studied the expressions of both Mina53, which is a myc target gene and is related to cell proliferation, and Cap43, which is related to metastasis suppression and downregulation of MYCN gene, in neuroblastoma.


METHODS
Forty-eight surgically obtained neuroblastoma specimens were immunohistochemically stained. The Cap43 and Mina53 expression levels were determined, and their relationship to clinical prognostic factors, biological prognostic factors, and the patients' prognosis were examined.


RESULTS
The Cap43 expression score was significantly high in the cases that had one of the good prognostic factors (<1 year old, early stage, mass screening case, no MYCN gene amplification), whereas the Mina53 expression score was high in those with poor prognostic factors. Regarding the MYCN expression site, the Cap43 expression score was significantly high in the cases demonstrating cytoplasm expression, whereas the Mina53 expression score was significantly high in the cases demonstrating nucleus expression. A significant relationship was found between Cap43 and TrkA, between Mina53 and Ki-67, and between Mina53 and TrkA. The prognosis was significantly favorable in the Cap43 high-expression cases, whereas it was significantly poor in the Mina53 high-expression cases.


CONCLUSIONS
Cap43 and Mina53 are both considered to be important biological and prognostic factors in neuroblastoma.
Fukahori
Suguru
S
Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Yano
Hirohisa
H
Tsuneoka
Makoto
M
Tanaka
Yoshiaki
Y
Yagi
Minoru
M
Kuwano
Michihiko
M
Tajiri
Tatsuro
T
Taguchi
Tomoaki
T
Tsuneyoshi
Masazumi
M
Kojiro
Masamichi
M
D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000032:analysis; D018797:Cell Cycle Proteins / Q000235:genetics* / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D049308:Dioxygenases; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016259:Genes, myc / Q000235:genetics; D020022:Genetic Predisposition to Disease; D056466:Histone Demethylases; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics* / Q000378:metabolism; D008297:Male; D015999:Multivariate Analysis; D009447:Neuroblastoma / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D009687:Nuclear Proteins / Q000235:genetics*; D011336:Probability; D011379:Prognosis; D016016:Proportional Hazards Models; D020917:Receptor, trkA / Q000235:genetics; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D018709:Statistics, Nonparametric; D016019:Survival Analysis; D000099259:N-myc Downstream-Regulated Gene 1 Protein
D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D049308:Dioxygenases; D056466:Histone Demethylases; D047908:Intracellular Signaling Peptides and Proteins; D009687:Nuclear Proteins; D020917:Receptor, trkA; D000099259:N-myc Downstream-Regulated Gene 1 Protein; C466777:RIOX2 protein, human